Fidelity Investments
CTKB icon

Fidelity Investments’s Cytek Biosciences CTKB Stock Holding History

Fidelity Investments’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.23M Buy
504,385
+220,999
+78% +$943K ﹤0.01% 2715
2026
Q1 		$1.24M Buy
283,386
+49,314
+21% +$233K ﹤0.01% 2798
2025
Q4 		$1.18M Buy
234,072
+53,286
+29% +$247K ﹤0.01% 2792
2025
Q3 		$627K Sell
180,786
-24,955
-12% -$93.7K ﹤0.01% 2958
2025
Q2 		$700K Sell
205,741
-511,419
-71% -$1.7M ﹤0.01% 2844
2025
Q1 		$2.88M Buy
717,160
+33,973
+5% +$176K ﹤0.01% 2334
2024
Q4 		$4.43M Buy
683,187
+16,111
+2% +$96K ﹤0.01% 2200
2024
Q3 		$3.7M Buy
667,076
+30,386
+5% +$172K ﹤0.01% 2216
2024
Q2 		$3.55M Buy
636,690
+114,302
+22% +$687K ﹤0.01% 2185
2024
Q1 		$3.51M Sell
522,388
-23
-0% -$182 ﹤0.01% 2177
2023
Q4 		$4.76M Buy
522,411
+2,668
+0.5% +$16.8K ﹤0.01% 2082
2023
Q3 		$2.87M Buy
519,743
+375
+0.1% +$3.01K ﹤0.01% 2184
2023
Q2 		$4.44M Buy
519,368
+1,208
+0.2% +$10.8K ﹤0.01% 2100
2023
Q1 		$4.76M Sell
518,160
-17,501
-3% -$188K ﹤0.01% 2108
2022
Q4 		$5.47M Sell
535,661
-59,412
-10% -$798K ﹤0.01% 2090
2022
Q3 		$8.76M Buy
595,073
+74,228
+14% +$964K ﹤0.01% 1959
2022
Q2 		$5.59M Buy
520,845
+2,616
+0.5% +$26K ﹤0.01% 2202
2022
Q1 		$5.59M Sell
518,229
-2,148,371
-81% -$29M ﹤0.01% 2336
2021
Q4 		$43.5M Hold
2,666,600
– – ﹤0.01% 1483
2021
Q3 		$57.1M Buy
+2,666,600
New +$62.7M ﹤0.01% 1358

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fidelity Investments's CTKB Position: Q2 2026 in Review

Fidelity Investments increased its Cytek Biosciences (CTKB) stake by 78% in Q2 2026, buying an estimated $943K and bringing the position to 504,385 shares worth $2.23M. The position accounts for ﹤0.01% of the portfolio, ranked #2715.

Fidelity Investments first reported a position in CTKB in Q3 2021 and has held it in 20 quarters since. The position peaked at $57.1M in Q3 2021. 155 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • Fidelity Investments held 504,385 shares of Cytek Biosciences worth $2.23M as of Q2 2026.
  • Fidelity Investments bought 220,999 Cytek Biosciences shares in Q2 2026, an estimated $943K.
  • Cytek Biosciences made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #2715 holding.
  • Fidelity Investments first reported a position in Cytek Biosciences in Q3 2021 and has held it in 20 quarters since.
  • Fidelity Investments's Cytek Biosciences position peaked at $57.1M in Q3 2021.
  • 155 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.